Suppression of the Ph chromosome accompanied by complete hematological repression has been seen with IFN-α administration [120], but as in some of the other malignancies mentioned above, higher response rates have been observed in CML when IFN-α is used in combination with chemotherapy (e.g. cytosine arabinoside) [121]. The gene discussed is IFNA2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.